IHC is currently the gold standard method in routine pathological diagnosis, including the semiquantitative determination of Estrogen Receptor 1 (ESR1), Progesterone Receptor (PGR) and Human Epidermal Growth Factor Receptor 2 (HER2) receptor status in breast tumors. This evidence concerns the gene ERBB2 and breast neoplasm.